The Business of Better Sperm: Why Sperm Motility Could Be an Untapped Value Driver in Fertility Innovation

The fertility industry has become remarkably sophisticated at measuring, selecting and manipulating embryos. But before an embryo exists, there is another critical biological starting point: the sperm.

Sperm count, morphology nd motility have long been standard components of semen analysis. Yet sperm motility is often treated primarily as a diagnostic parameter rather than as a potential performance variable within assisted reproductive technology (ART).

For fertility clinics, IVF laboratories, technology companies and investors, innovations that improve the functional population of sperm could potentially create value at multiple points in the reproductive process—from sperm preparation and selection to treatment efficiency and downstream clinical outcomes.

The opportunity is not simply about producing a better semen-analysis number. It’s about asking, “What could happen if we could reliably improve the number of functionally capable sperm available to an ART procedure?”

From a laboratory metric to a value driver

Sperm motility describes the ability of sperm to move. In reproductive biology, however, movement is more than a number on a laboratory report. Sperm must navigate a complex biological environment to reach and interact with the egg. In ART, sperm are also subjected to laboratory preparation and selection processes designed to concentrate the population most suitable for the procedure.

This makes the post-preparation functional sperm population particularly relevant. Research has investigated the relationship between total motile sperm count and IUI outcomes. A 2026 systematic review and meta-analysis covering more than 110,000 IUI cycles found that higher post-wash total progressively motile sperm count was consistently associated with higher clinical pregnancy rates.

The important point is not that more motile sperm guarantees pregnancy—it does not. Rather, it demonstrates why the functional sperm population available to an ART procedure is an important variable worth optimizing. And that creates an important innovation question, “Can technology improve that starting point?”

Why upstream improvements matter

IVF laboratories operate within a highly measurable environment. Clinics and laboratories track performance across multiple structural, process and outcome measures, including fertilization, embryo development, utilization and cumulative live birth. This creates an opportunity for innovation at every stage of the workflow.

Consider the basic chain: Sperm sample → preparation → usable sperm population → fertilization → embryo development → transfer → pregnancy → live birth

Every stage presents opportunities for variability and loss. If an innovation can improve the functional sperm population entering the process, it becomes reasonable to investigate whether that improvement can create measurable downstream benefits.

Those benefits might include:

• More sperm available for selection

• Improved consistency of sperm preparation

• A greater proportion of samples meeting procedural thresholds

• Additional options for clinicians in certain cases

• Potential improvements in relevant ART laboratory metrics

• Potential downstream clinical benefits

Not every effect will occur in every patient or procedure. That is precisely why rigorous validation matters. The objective should be to determine where an improvement in sperm function creates measurable value. The value of a fertility innovation is rarely determined by a single laboratory measurement. It is determined by what that measurement means downstream. For an IVF clinic, improved treatment performance could potentially create value in several ways.

Improved laboratory efficiency and potentially greater treatment value

IVF is a resource-intensive process involving physicians, embryologists, laboratory infrastructure, equipment and consumables. A technology that improves an upstream component of the process could potentially increase the value generated from that existing infrastructure—without requiring the laboratory to fundamentally redesign its workflow.

Because IVF laboratories operate within tightly controlled environments where consistency, quality and throughput matter, an innovation that can be integrated into established sperm-preparation workflows may have an attractive commercial profile because it can potentially enhance an existing process rather than require an entirely new one.

For patients, unsuccessful treatment can mean additional financial, emotional and physical costs. For clinics, unsuccessful cycles also represent significant utilization of resources without achieving the desired endpoint. This makes technologies that can potentially improve upstream performance worth investigating for their downstream clinical and economic impact.

Where Aqua Fem fits

This is the opportunity Aqua Fem is exploring with AF, a novel approach intended to enhance sperm motility for ART-related applications. In Aqua Fem's preclinical testing, AF has demonstrated greater than 700% increases in sperm motility following contact under the conditions tested.

That finding raises a much larger question: Can a substantial improvement in sperm motility become a meaningful improvement in reproductive performance and can it create measurable downstream benefits within the ART workflow?

At Aqua Fem, we believe that question deserves rigorous investigation, and why we’re currently working with external partners to strengthen the evidence base surrounding AF and its effects on sperm motility. The goal is not simply to demonstrate that AF changes a laboratory measurement, but to understand what that change means.

A new way to think about male fertility innovation

Male fertility has often been treated primarily as the diagnostic side of the fertility equation: obtain a semen analysis, identify abnormalities and determine the next step. But sperm are not simply numbers on a laboratory report. They are functional cells participating in one of the most complex processes in human biology.

As reproductive medicine becomes increasingly data-driven, there is an opportunity to look more closely at sperm function and ask how improving that function could affect the performance of the broader ART system.

That is the opportunity we’re exploring at Aqua Fem with AF. The goal is not to promise outcomes that current evidence cannot yet support. It is to identify, validate and ultimately translate a potentially significant improvement in sperm motility into measurable clinical and commercial value.

Because in fertility innovation, the most valuable technology may not simply be the one that produces the biggest laboratory effect. It may be the one that can demonstrate what that effect means downstream.